Research ExplorerPublicationsChallenges and Opportunities for Real-World Evidence in Meta...

Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer

Standard

Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer. / Lüftner, Diana; Hartkopf, Andreas D; Lux, Michael P; Overkamp, Friedrich; Tesch, Hans; Titzmann, Adriana; Pöschke, Patrik; Wallwiener, Markus; Müller, Volkmar; Beckmann, Matthias W; Belleville, Erik; Janni, Wolfgang; Fehm, Tanja N; Kolberg, Hans-Christian; Ettl, Johannes; Wallwiener, Diethelm; Schneeweiss, Andreas; Brucker, Sara Y; Fasching, Peter A.

In: BREAST CARE, Vol. 16, No. 2, 04.2021, p. 108-114.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Lüftner, D, Hartkopf, AD, Lux, MP, Overkamp, F, Tesch, H, Titzmann, A, Pöschke, P, Wallwiener, M, Müller, V, Beckmann, MW, Belleville, E, Janni, W, Fehm, TN, Kolberg, H-C, Ettl, J, Wallwiener, D, Schneeweiss, A, Brucker, SY & Fasching, PA 2021, 'Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer', BREAST CARE, vol. 16, no. 2, pp. 108-114. https://doi.org/10.1159/000515701

APA

Lüftner, D., Hartkopf, A. D., Lux, M. P., Overkamp, F., Tesch, H., Titzmann, A., Pöschke, P., Wallwiener, M., Müller, V., Beckmann, M. W., Belleville, E., Janni, W., Fehm, T. N., Kolberg, H-C., Ettl, J., Wallwiener, D., Schneeweiss, A., Brucker, S. Y., & Fasching, P. A. (2021). Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer. BREAST CARE, 16(2), 108-114. https://doi.org/10.1159/000515701

Vancouver

Lüftner D, Hartkopf AD, Lux MP, Overkamp F, Tesch H, Titzmann A et al. Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer. BREAST CARE. 2021 Apr;16(2):108-114. https://doi.org/10.1159/000515701

Bibtex

@article{69e338bf2f2649f1982bad57c6986fe3,
title = "Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer",
abstract = "Background: The therapeutic armamentarium for patients with metastatic breast cancer is becoming more and more specific. Recommendations from clinical trials are not available for all treatment situations and patient subgroups, and it is therefore important to collect real-world data.Summary: To develop recommendations for up-to-date treatments and participation in clinical trials for patients with metastatic breast cancer, the Prospective Academic Translational Research PRAEGNANT Network was established to optimize the quality of oncological care in the advanced therapeutic setting. The main aim of PRAEGNANT is to systematically record medical care for patients with metastatic breast cancer in the real-life setting, including the outcome and side effects of different treatment strategies, to monitor quality-of-life changes during therapy, to identify patients eligible for participation in clinical studies, and to allow targeted therapies based on the molecular structures of breast carcinomas.Key Messages: This article describes the PRAEGNANT network and sheds light on the question of whether the various end points from clinical trials can be transferred to the real-world treatment situation.",
author = "Diana L{\"u}ftner and Hartkopf, {Andreas D} and Lux, {Michael P} and Friedrich Overkamp and Hans Tesch and Adriana Titzmann and Patrik P{\"o}schke and Markus Wallwiener and Volkmar M{\"u}ller and Beckmann, {Matthias W} and Erik Belleville and Wolfgang Janni and Fehm, {Tanja N} and Hans-Christian Kolberg and Johannes Ettl and Diethelm Wallwiener and Andreas Schneeweiss and Brucker, {Sara Y} and Fasching, {Peter A}",
note = "Copyright {\textcopyright} 2021 by S. Karger GmbH, Freiburg.",
year = "2021",
month = apr,
doi = "10.1159/000515701",
language = "English",
volume = "16",
pages = "108--114",
journal = "BREAST CARE",
issn = "1661-3791",
publisher = "S. Karger AG",
number = "2",

}

RIS

TY - JOUR

T1 - Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer

AU - Lüftner, Diana

AU - Hartkopf, Andreas D

AU - Lux, Michael P

AU - Overkamp, Friedrich

AU - Tesch, Hans

AU - Titzmann, Adriana

AU - Pöschke, Patrik

AU - Wallwiener, Markus

AU - Müller, Volkmar

AU - Beckmann, Matthias W

AU - Belleville, Erik

AU - Janni, Wolfgang

AU - Fehm, Tanja N

AU - Kolberg, Hans-Christian

AU - Ettl, Johannes

AU - Wallwiener, Diethelm

AU - Schneeweiss, Andreas

AU - Brucker, Sara Y

AU - Fasching, Peter A

N1 - Copyright © 2021 by S. Karger GmbH, Freiburg.

PY - 2021/4

Y1 - 2021/4

N2 - Background: The therapeutic armamentarium for patients with metastatic breast cancer is becoming more and more specific. Recommendations from clinical trials are not available for all treatment situations and patient subgroups, and it is therefore important to collect real-world data.Summary: To develop recommendations for up-to-date treatments and participation in clinical trials for patients with metastatic breast cancer, the Prospective Academic Translational Research PRAEGNANT Network was established to optimize the quality of oncological care in the advanced therapeutic setting. The main aim of PRAEGNANT is to systematically record medical care for patients with metastatic breast cancer in the real-life setting, including the outcome and side effects of different treatment strategies, to monitor quality-of-life changes during therapy, to identify patients eligible for participation in clinical studies, and to allow targeted therapies based on the molecular structures of breast carcinomas.Key Messages: This article describes the PRAEGNANT network and sheds light on the question of whether the various end points from clinical trials can be transferred to the real-world treatment situation.

AB - Background: The therapeutic armamentarium for patients with metastatic breast cancer is becoming more and more specific. Recommendations from clinical trials are not available for all treatment situations and patient subgroups, and it is therefore important to collect real-world data.Summary: To develop recommendations for up-to-date treatments and participation in clinical trials for patients with metastatic breast cancer, the Prospective Academic Translational Research PRAEGNANT Network was established to optimize the quality of oncological care in the advanced therapeutic setting. The main aim of PRAEGNANT is to systematically record medical care for patients with metastatic breast cancer in the real-life setting, including the outcome and side effects of different treatment strategies, to monitor quality-of-life changes during therapy, to identify patients eligible for participation in clinical studies, and to allow targeted therapies based on the molecular structures of breast carcinomas.Key Messages: This article describes the PRAEGNANT network and sheds light on the question of whether the various end points from clinical trials can be transferred to the real-world treatment situation.

U2 - 10.1159/000515701

DO - 10.1159/000515701

M3 - SCORING: Review article

C2 - 34007260

VL - 16

SP - 108

EP - 114

JO - BREAST CARE

JF - BREAST CARE

SN - 1661-3791

IS - 2

ER -